Zymeworks (ZYME) Equity Average (2021 - 2026)

Zymeworks' Equity Average history runs 6 years deep, the most recent figure standing at $216.0 million for Q1 2026.

• In Q1 2026, Equity Average fell 34.9% year-over-year to $216.0 million; the TTM figure through Mar 2026 stood at $216.0 million (down 34.9% YoY), while the FY2025 annual figure was $303.6 million, down 24.43% from the prior year.
• Equity Average came in at $216.0 million for Q1 2026 at Zymeworks, down from $294.3 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $483.2 million in Q1 2023 to a low of $201.0 million in Q3 2022.
• A 5-year average of $352.5 million and a median of $336.4 million in 2022 frame the typical range for Equity Average.
• Across the five-year window, Equity Average soared 117.21% in 2023 and slumped 34.9% in 2026, its largest moves.
• Zymeworks' Equity Average stood at $336.4 million in 2022, then surged by 32.17% to $444.6 million in 2023, then retreated by 20.63% to $352.9 million in 2024, then retreated by 16.6% to $294.3 million in 2025, then dropped by 26.59% to $216.0 million in 2026.
• According to Business Quant data, Equity Average over the past three periods registered $216.0 million, $294.3 million, and $327.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison